Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Real Time Quote from BATS)

$17.98 USD

17.98
5,386,889

+0.10 (0.56%)

Updated Sep 19, 2024 09:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 15% (38 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Teva (TEVA) Q3 Earnings Miss, Cuts 2017 View, Stock Falls

by Zacks Equity Research

Teva (TEVA) third quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.

    Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View

    by Zacks Equity Research

    Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.

      Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?

      by Zacks Equity Research

      Teva's (TEVA) generic segment may continue to see weakness due to significant competitive and pricing pressure in the U.S. generics industry, which will continue to hurt the top line.

        Teva Submits BLA to FDA for Migraine Candidate Fremanezumab

        by Zacks Equity Research

        Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States.

          Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

          by Zacks Equity Research

          Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

            Arpita Dutt headshot

            Pricing Pressure, Competition Remain Headwinds for Pharma Stocks

            by Arpita Dutt

            Although the pharma and biotech sectors have rebounded in 2017, drug companies may find it a bit difficult to justify their high prices.

              Tracey Ryniec headshot

              Where to Find Value in Healthcare Stocks

              by Tracey Ryniec

              The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

                Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall

                by Zacks Equity Research

                Allergan (AGN) lost a patent infringement lawsuit filed against companies trying to develop a generic version of its eye drug, Restasis, which is also its second bestselling drug.

                  Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

                  by Zacks Equity Research

                  Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

                    Arpita Dutt headshot

                    Pharma Industry Outlook - October 2017

                    by Arpita Dutt

                    New product sales ramping up, R&D success and innovation, strong results, a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector.

                      Mylan Gets Complete Response Letter For Biosimilar Neulasta

                      by Zacks Equity Research

                      Mylan (MYL) suffered a setback following the FDA's CRL for the company's BLA for MYL-1401H, a proposed biosimilar of Neulasta.

                        Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute

                        by Zacks Equity Research

                        Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.

                          Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early

                          by Zacks Equity Research

                          Teva's (TEVA) shares plunged after Mylan announced an earlier-than-expected launch of its generic version of the 40-mg thrice-weekly formulation of its blockbuster multiple sclerosis drug, Copaxone.

                            Ryan McQueeney headshot

                            Teva Shares Plummet After Mylan's Copaxone Generic Gets FDA Approval

                            by Ryan McQueeney

                            Shares of Teva Pharmaceuticals (TEVA) opened more than 13% lower on Wednesday, plunging close to their 52-week low in the process. The struggling Israeli pharma firm, which has faced significant pressure to reduce its debt load, is sliding once again--this time because of a brand new competitor.

                              Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg

                              by Zacks Equity Research

                              Mylan N.V. (MYL) gets a boost with the FDA's approval of the generic version of multiple sclerosis drug Copaxone.

                                Allergan's Botox Gets FDA Nod for Forehead Line Treatment

                                by Zacks Equity Research

                                Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.

                                  Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes

                                  by Zacks Equity Research

                                  Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.

                                    Teva Reintroduces Generic Depo-Provera Injection in U.S.

                                    by Zacks Equity Research

                                    Teva (TEVA) announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection 150 mg/mL in the United States.

                                      Impax Generic Division Progresses Well Amid Pricing Pressure

                                      by Zacks Equity Research

                                      Impax Laboratories' (IPXL) generic portfolio has progressed well so far this year. Moreover, approval of the generic versions of Vytorin and Concerta is a positive.

                                        Allergan Authorizes New $2B Share Buyback Plan, Stock Up

                                        by Zacks Equity Research

                                        Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.

                                          Teva/Nuvelution to Speed Up Development of Austedo in US

                                          by Zacks Equity Research

                                          Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.

                                            Teva's Leukemia Drug sNDA Granted Priority Review by the FDA

                                            by Zacks Equity Research

                                            Teva Pharmaceutical's (TEVA) sNDA for label expansion of Trisenox as first-line treatment of acute promyelocytic leukemia has been accepted by the FDA under priority review.

                                              Company News For Sep 13, 2017

                                              by Zacks Equity Research

                                              Companies in the news are: TEVA,WDC,AMZN,LMNR

                                                Teva's New CEO Brings No Relief: Generic Drugmakers to Dump

                                                by Zacks Equity Research

                                                The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.

                                                  Company News For Sep 12, 2017

                                                  by Zacks Equity Research

                                                  Companies in the news are: TEVA,BMY,EFX,FB